reMYND

Belgium
Leuven, Flanders, Belgium, BE-3001

Company profile

reMYND company profile

Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models. They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept.

Business identity

Contact email
[email protected]
Phone number
+32 16 75 14 20
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2012-01-01, Year

Headquarters

Postal code
BE-3001
Country code
BE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$28.2M
Last funding
Series B / $14.6M / 2021-01-21
Last equity funding
Series B / $14.6M
Investors
8
Lead investors
2
Founders
1
Articles
6

Founders and investors

Founders

Joris Winderickx

Lead investors

KorysPMV

Investors

BNP Paribas FortisGemma Frisius FundKorysKU LeuvenPMV